title: A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients.
abstract: Double-dose hepatitis B virus revaccination of human immunodeficiency virus (HIV)-infected patients proved to be effective in 50.7% of 144 patients who had previously failed to respond to standard doses. In the multivariate analysis, female patients were found to have a significantly better response (P= .03). The effect of age on the response depended on the viral load at the time of revaccination. For patients with a detectable HIV RNA load, the effect of age was stronger (odds ratio [OR], 0.34 per 10 years older [95% confidence interval {CI}, 0.16-0.72]; P= .005) than for patients with an undetectable HIV RNA load (OR, 0.74 per 10 years older [95% CI, 0.50-1.09]; P= .12).
authors.affiliation: Departments of Internal Medicine, Infectious Diseases Section, Erasmus Medical Center, Rotterdam, The Netherlands. t.sluijs@erasmusmc.nl
authors.forename: Theodora E M S
authors.initials: TE
authors.lastname: de Vries-Sluijs
authors.forename: Bettina E
authors.initials: BE
authors.lastname: Hansen
authors.forename: Gerard J J
authors.initials: GJ
authors.lastname: van Doornum
authors.forename: Tirza
authors.initials: T
authors.lastname: Springeling
authors.forename: Nicole M
authors.initials: NM
authors.lastname: Evertsz
authors.forename: Robert A
authors.initials: RA
authors.lastname: de Man
authors.forename: Marchina E
authors.initials: ME
authors.lastname: van der Ende
mesh_terms: D000328:Adult; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000502:physiology; D006509:Hepatitis B / Q000150:complications / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage* / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood; D016896:Treatment Outcome; D014614:Vaccines, Synthetic / Q000008:administration & dosage* / Q000276:immunology / Q000627:therapeutic use
chemical_list: D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D012367:RNA, Viral; D014614:Vaccines, Synthetic